AREG ELISA kit (Human)

SKU: SEA006Hu

Size: 96Tests

# of Times Cited in literature: 7

Prepare Time: 1-3 days(please inquire for mutiple units)

Target Name: AREG

Target Full Name: Amphiregulin

Alternative Names: AR; CRDGF; SDGF; Colorectum Cell-Derived Growth Factor; Schwannoma-Derived Growth Factor

Target Species: Human

Uniprot: P15514

Gene ID: 374

Featured Series: SE kit

Featured Series Function: Detects protein (regular version)

Specificity: Reactive with Human AREG / Amphiregulin

Method: Colormetric

Detection principle: Double-antibody Sandwich

Detection range: 15.6-1,000pg/mL

Sensitivity: 6.5pg/mL

Assay Time: 3h

Sample Size: 100uL

Recommended/Predicted Sample Types: Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates and other Biological Fluids

Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%

Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Amphiregulin (AREG) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Amphiregulin (AREG) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100

Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)

Shelf-life: 12 months

Specificity: This assay has high sensitivity and excellent specificity for detection of Amphiregulin (AREG). No significant cross-reactivity or interference between Amphiregulin (AREG) and analogues was observed.

Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C; 3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C; 4. Aspirate and wash 3 times; 5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 6. Aspirate and wash 5 times; 7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 8. Add 50µL Stop Solution. Read at 450nm immediately.

Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Amphiregulin (AREG). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Amphiregulin (AREG). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Amphiregulin (AREG), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Amphiregulin (AREG) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Research Area: Cytokine;Tumor immunity;

References Citing This Product: Amphiregulin and Epiregulin Expression in Colorectal Carcinoma and the Correlation with Clinicopathological Characteristics

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer

Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer

Serum level of hepatocyte growth factor is a novel marker of predicting theoutcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer

CD9 regulates keratinocyte migration by negatively modulating the sheddase activity of ADAM17

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine

Polarization of ADAM17‐driven EGFR signalling in electric field‐guided collective migration of epidermal sheets